Yen M H, Wu C C, Chiou W F, Liao C H
Department of Pharmacology, National Defense Medical Center, Taipei, Taiwan, Republic of China.
Proc Natl Sci Counc Repub China B. 1989 Apr;13(2):83-8.
The mechanism of the vasodilator effect of hydralazine on isolated rat aorta was studied. Results demonstrated that the vasodilator effect of hydralazine was greater on intact aortas than on endothelium-denuded preparations, particularly at low concentrations of between 0.1 mM and 0.5 mM. In addition, hydralazine did not have any effect on cyclic GMP levels. We also found that methylene blue, an inhibitor of guanylate cyclase, completely abolished the vasorelaxant action of nitroglycerin but not that of hydralazine. These results indicate that the vasodilator effect of hydralazine was not due to elevating the cyclic GMP levels. On the other hand, hydralazine significantly inhibited both the contractions induced by norepinephrine and/or high-potassium. In conclusion, a part of the vasodilator effect of hydralazine seems to depend on the integrity of the vascular endothelium. However, this vasodilator effect was not associated with any elevation in cyclic GMP level. Thus, the direct vasodilator action of hydralazine may be related to its interference with the movement and/or translocation of calcium across the cell membrane.
研究了肼屈嗪对离体大鼠主动脉的血管舒张作用机制。结果表明,肼屈嗪对完整主动脉的血管舒张作用大于对去内皮制剂的作用,尤其是在0.1 mM至0.5 mM的低浓度时。此外,肼屈嗪对环磷酸鸟苷(cGMP)水平没有任何影响。我们还发现,鸟苷酸环化酶抑制剂亚甲蓝完全消除了硝酸甘油的血管舒张作用,但没有消除肼屈嗪的作用。这些结果表明,肼屈嗪的血管舒张作用不是由于提高了cGMP水平。另一方面,肼屈嗪显著抑制了去甲肾上腺素和/或高钾诱导的收缩。总之,肼屈嗪的部分血管舒张作用似乎取决于血管内皮的完整性。然而,这种血管舒张作用与cGMP水平的任何升高均无关。因此,肼屈嗪的直接血管舒张作用可能与其干扰钙跨细胞膜的移动和/或转运有关。